(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen (NASDAQ:BIIB)'s Alzheimer's drug Leqembi, the... On Monday, Bernstein ...
Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc.?and?full Prescribing Information?for SPINRAZA in the U.S., or visit your ...
Two of the newest drugs to treat the disease are currently available in the U.S. Lecanemab, from Biogen and Japanese partner Eisai Co., is sold under the brand name Leqembi, and donanemab from Eli ...
The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...
In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and ...
U.S. biotech company Biogen, which commercialized a new treatment for Alzheimer's disease in collaboration with Japanese pharmaceutical company Eisai, is aiming to launch a subcutaneous injection ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for an injectable formulation of their Alzheimer’s disease (AD) drug ...
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with ...
That experience didn't dissuade the company from advancing another Alzheimer's candidate. Leqembi (lecanemab), codeveloped by Biogen and Eisai, in 2023 became the second drug in the anti-amyloid class ...